FDA approves oral dermatomyositis therapy
Phase 3 findings show improvements in physical function and skin disease activity.
By
Kathryn Wighton
August 28, 2026
Clinical Scorecard: FDA approves oral dermatomyositis therapy
At a Glance
Category Detail
Condition Dermatomyositis Key Mechanisms Brepocitinib is a Janus kinase and tyrosine kinase 2 inhibitor that blocks immune and inflammatory pathways. Target Population Adults with dermatomyositis Care Setting Clinical treatment for autoimmune conditions
Key Highlights
First FDA-approved oral treatment for dermatomyositis. Brepocitinib showed improved Total Improvement Scores at week 52. Participants receiving brepocitinib had reduced corticosteroid use. Common adverse reactions included upper respiratory tract infection and headache. Brepocitinib carries a boxed warning for serious infections and other risks. Guideline-Based Recommendations
Diagnosis
Diagnosis of dermatomyositis based on clinical criteria and muscle biopsy. Management
Brepocitinib is indicated for the treatment of adults with dermatomyositis. Monitoring & Follow-up
Monitor for adverse reactions and treatment efficacy at regular intervals. Risks
Serious infections, increased all-cause mortality, malignancies, major adverse cardiovascular events, and thrombosis. Patient & Prescribing Data
Adults diagnosed with dermatomyositis.
Brepocitinib is administered once daily and may reduce the need for corticosteroids.
Clinical Best Practices
Evaluate Total Improvement Score to assess treatment efficacy. Consider risk factors before prescribing brepocitinib. Related Resources & Content
